You can buy or sell PTGX and other stocks, options, ETFs, and crypto commission-free!
Protagonist Therapeutics, Inc. Common Stock, also called Protagonist Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Read More The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
52 Week High
52 Week Low
Expected Nov 5, Pre-Market